Pharmaceutical giant Pfizer vowed today to stop the time-tested habit of jacking up the list prices of its drugs each year and indicated it would also lower the prices of some of its products, such as the breast cancer drug Ibrance. The announcement came as the company is under scrutiny for its proposed merger with the company Allergan, which critics have alleged is a way for the company to save billions of dollars in taxes by relocating its headquarters abroad.